Taleb Altel

Dr. Taleb Altel

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
IGIzeia Lukin Garmendia
Izeia Lukin Garmendia
IEItsasne Erezuma
Itsasne Erezuma
LMLidia Maeso
Lidia Maeso
JZJon Zarate
Jon Zarate
Martin DesimoneMartin Desimone
Martin Desimone
GOGorka Orive
Gorka Orive
Tissue engineering has become a medical alternative in this society with an ever-increasing lifespan. Advances in the areas of technology and biomaterials have facilitated the use of engineered constructs for medical issues. This review discusses on-going concerns and the latest developments in a widely employed biomaterial in the field of tissue engineering: gelatin. Emerging techniques including 3D bioprinting and gelatin functionalization have demonstrated better mimicking of native tissue by reinforcing gelatin-based systems, among others. This breakthrough facilitates, on the one hand, the manufacturing process when it comes to practicality and cost-effectiveness, which plays a key role in the transition towards clinical application. On the other hand, it can be concluded that gelatin could be considered as one of the promising biomaterials in future trends, in which the focus might be on the detection and diagnosis of diseases rather than treatment.

26 July 2019 in Medicinal Research Reviews
Verified
Journal Article
Closed access
NMNour M. Moussa‐Pacha
Nour M. Moussa‐Pacha
SAShifaa M. Abdin
Shifaa M. Abdin
HOHany A. Omar
Hany A. Omar
HAHasan Alniss
Hasan Alniss
TATaleb Altel
Taleb Altel

1 May 2011 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TATaleb Altel
Taleb Altel
RARaed A. Al-Qawasmeh
Raed A. Al-Qawasmeh
Rania Faouzi ZaarourRania Faouzi Zaarour
Rania Faouzi Zaarour

1 November 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NKNoura Khaiwa
Noura Khaiwa
NMNoor R. Maarouf
Noor R. Maarouf
MDMhd H. Darwish
Mhd H. Darwish
DADima W.M. Alhamad
Dima W.M. Alhamad
ASAnusha Sebastian
Anusha Sebastian
TATaleb Altel
Taleb Altel

5 August 2014 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
MAMustafa T. Ardah
Mustafa T. Ardah
KPKaterina E. Paleologou
Katerina E. Paleologou
GLGuohua Lv
Guohua Lv
SKSalema B. Abul Khair
Salema B. Abul Khair
AKAbdulla S. Kazim
Abdulla S. Kazim
OEOmar El-Agnaf
Omar El-Agnaf
The aggregation of α-synuclein (α-syn) is considered the key pathogenic event in many neurological disorders such as Parkinson’s disease (PD), dementia with Lewy bodies and multiple system atrophy, giving rise to a whole category of neurodegenerative diseases known as synucleinopathies. Although the molecular basis of α-syn toxicity has not been precisely elucidated, a great deal of effort has been put into identifying compounds that could inhibit or even reverse the aggregation process. Previous reports indicated that many phenolic compounds are potent inhibitors of α-syn aggregation. The aim of the present study was to assess the anti-aggregating effect of gallic acid (GA) (3,4,5-trihydroxybenzoic acid), a benzoic acid derivative that belongs to a group of phenolic compounds known as phenolic acids. By employing an array of biophysical and biochemical techniques and a cell-viability assay, GA was shown not only to inhibit α-syn fibrillation and toxicity but also to disaggregate preformed α-syn amyloid fibrils. Interestingly, GA was found to bind to soluble, non-toxic oligomers with no β-sheet content, and to stabilize their structure. The binding of GA to the oligomers may represent a potential mechanism of action. Additionally, by using structure activity relationship data obtained from fourteen structurally similar benzoic acid derivatives, it was determined that the inhibition of α-syn fibrillation by GA is related to the number of hydroxyl moieties and their position on the phenyl ring. GA may represent the starting point for designing new molecules that could be used for the treatment of PD and related disorders.

21 February 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PAPablo Edmundo Antezana
Pablo Edmundo Antezana
Sofia MunicoySofia Municoy
Sofia Municoy
MEMaria Ines Alvarez echazu
Maria Ines Alvarez echazu
PSPablo Luis Santo-Orihuela
Pablo Luis Santo-Orihuela
PCPaolo Nicolás Catalano
Paolo Nicolás Catalano
Martin DesimoneMartin Desimone
Martin Desimone
Skin tissue engineering and regeneration aim at repairing defective skin injuries and progress in wound healing. Until now, even though several developments are made in this field, it is still challenging to face the complexity of the tissue with current methods of fabrication. In this review, short, state-of-the-art on developments made in skin tissue engineering using 3D bioprinting as a new tool are described. The current bioprinting methods and a summary of bioink formulations, parameters, and properties are discussed. Finally, a representative number of examples and advances made in the field together with limitations and future needs are provided.